• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过小脑延髓池向MPS IIIA小鼠的脑脊液中注射重组人硫酸酯酶。

Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.

作者信息

Hemsley Kim M, King Barbara, Hopwood John J

机构信息

Lysosomal Diseases Research Unit, Department of Genetic Medicine, Children, Youth and Women's Health Service, Adelaide 5006, Australia.

出版信息

Mol Genet Metab. 2007 Mar;90(3):313-28. doi: 10.1016/j.ymgme.2006.10.005. Epub 2006 Dec 12.

DOI:10.1016/j.ymgme.2006.10.005
PMID:17166757
Abstract

At present, there is no widely available, safe and effective treatment for lysosomal storage disorders (LSD) that affect the brain. We have used a naturally occurring mouse model of mucopolysaccharidosis type IIIA (MPS IIIA) or Sanfilippo syndrome, to evaluate the effect of repeated injection of recombinant human sulfamidase (rhSGSH) into the cerebrospinal fluid via the cisterna magna (CM) on central nervous system (CNS) pathology and behavioral function. Mice received up to seven injections of rhSGSH (5-20 microg rhSGSH per injection) or vehicle on a fortnightly or monthly basis. A dose-dependent reduction in the level of a heparan sulfate-derived monosulfated disaccharide was observed within the brain (up to 62% reduction compared with vehicle-treated MPS IIIA mice) and spinal cord (up to 71% reduction). Ultrastructural examination revealed a reduction in lysosomal vesicle formation in various cell types and fewer (ubiquitin-positive) axonal spheroids were observed in several brain regions. The biochemical changes were accompanied by improved behavior, particularly in mice-treated more frequently. A humoral immune response to rhSGSH was observed in treated animals. Intra-CM injection of lysosomal enzyme may therefore represent an immediately applicable method of treating the CNS effects of this and potentially other LSD that affect the brain.

摘要

目前,对于影响大脑的溶酶体贮积症(LSD),尚无广泛可用、安全有效的治疗方法。我们使用了III型黏多糖贮积症(MPS IIIA)或桑菲利波综合征的天然小鼠模型,来评估通过枕大池(CM)向脑脊液中反复注射重组人硫酸酰胺酶(rhSGSH)对中枢神经系统(CNS)病理和行为功能的影响。小鼠每隔两周或每月接受多达七次rhSGSH注射(每次注射5 - 20微克rhSGSH)或赋形剂注射。在脑内(与接受赋形剂治疗的MPS IIIA小鼠相比,减少高达62%)和脊髓中(减少高达71%)观察到硫酸乙酰肝素衍生的单硫酸化二糖水平呈剂量依赖性降低。超微结构检查显示,各种细胞类型中溶酶体囊泡形成减少,并且在几个脑区观察到较少的(泛素阳性)轴突球状体。生化变化伴随着行为改善,尤其是在接受更频繁治疗的小鼠中。在接受治疗的动物中观察到对rhSGSH的体液免疫反应。因此,通过CM注射溶酶体酶可能是一种可立即应用于治疗这种以及可能影响大脑的其他LSD对CNS影响的方法。

相似文献

1
Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.通过小脑延髓池向MPS IIIA小鼠的脑脊液中注射重组人硫酸酯酶。
Mol Genet Metab. 2007 Mar;90(3):313-28. doi: 10.1016/j.ymgme.2006.10.005. Epub 2006 Dec 12.
2
Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.鞘内注射硫酸氨基葡聚糖酶治疗亨特综合征 A 型犬的效果——原理验证研究。
Mol Genet Metab. 2009 Dec;98(4):383-92. doi: 10.1016/j.ymgme.2009.07.013. Epub 2009 Jul 28.
3
Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA.脑内注射硫酸酯酶可延缓小鼠MPS-IIIA的神经病理学进程。
Mol Genet Metab. 2004 Aug;82(4):273-85. doi: 10.1016/j.ymgme.2004.05.005.
4
Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.确定注射部位对MPS IIIA小鼠脑脊液内酶替代疗法疗效的作用。
Mol Genet Metab. 2015 May;115(1):33-40. doi: 10.1016/j.ymgme.2015.03.002. Epub 2015 Mar 12.
5
Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.高剂量化学修饰的芳基硫酸酯酶对 MPSIIIA 小鼠模型病理的影响。
Exp Neurol. 2011 Jul;230(1):123-30. doi: 10.1016/j.expneurol.2011.04.004. Epub 2011 Apr 16.
6
Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA.硫酸乙酰肝素衍生二糖作为小鼠ⅢA型黏多糖贮积症蓄积标志物的验证
Mol Genet Metab. 2006 Feb;87(2):107-12. doi: 10.1016/j.ymgme.2005.09.026. Epub 2005 Dec 13.
7
Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.从出生起进行酶替代疗法可延缓IIIA型粘多糖贮积症小鼠行为和学习问题的发展。
Pediatr Res. 2004 Jul;56(1):65-72. doi: 10.1203/01.PDR.0000129661.40499.12. Epub 2004 May 5.
8
Enzyme replacement reduces neuropathology in MPS IIIA dogs.酶替代疗法可减少 MPSIIIA 犬的神经病理学损伤。
Neurobiol Dis. 2011 Aug;43(2):422-34. doi: 10.1016/j.nbd.2011.04.014. Epub 2011 Apr 29.
9
Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.III型黏多糖贮积症C57BL/6同源近交系小鼠品系的特性分析
Brain Res. 2006 Aug 9;1104(1):1-17. doi: 10.1016/j.brainres.2006.05.079. Epub 2006 Jul 7.
10
Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.用于治疗神经疾病的静脉内和脑脊液内蛋白质递送的研究。
Eur J Neurosci. 2009 Mar;29(6):1197-214. doi: 10.1111/j.1460-9568.2009.06666.x.

引用本文的文献

1
Choroid plexus-targeted viral gene therapy for alpha-mannosidosis, a prototypical neurometabolic lysosomal storage disease.脉络丛靶向病毒基因疗法治疗α-甘露糖苷贮积症,一种典型的神经代谢性溶酶体贮积病。
Hum Mol Genet. 2025 Mar 20;34(7):577-585. doi: 10.1093/hmg/ddae201.
2
An immune deficient mouse model for mucopolysaccharidosis IIIA (Sanfilippo syndrome).用于黏多糖贮积症 IIIA 型(Sanfilippo 综合征)的免疫缺陷小鼠模型。
Sci Rep. 2023 Oct 27;13(1):18439. doi: 10.1038/s41598-023-45178-0.
3
Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.
靶向溶酶体贮积症的中枢神经系统:血脑屏障穿越的治疗策略。
Mol Ther. 2023 Mar 1;31(3):657-675. doi: 10.1016/j.ymthe.2022.11.015. Epub 2022 Nov 30.
4
Transduction characteristics of alternative adeno-associated virus serotypes in the cat brain by intracisternal delivery.经脑池内注射后猫脑中不同腺相关病毒血清型的转导特性
Mol Ther Methods Clin Dev. 2022 Jul 16;26:384-393. doi: 10.1016/j.omtm.2022.07.007. eCollection 2022 Sep 8.
5
Modified Protocol for Establishment of Intracranial Arterial Dolichoectasia Model by Injection of Elastase Into Cerebellomedullary Cistern in Mice.通过向小鼠小脑延髓池注射弹性蛋白酶建立颅内动脉扩张模型的改良方案
Front Neurol. 2022 Apr 18;13:860541. doi: 10.3389/fneur.2022.860541. eCollection 2022.
6
Mucopolysaccharidosis III: Molecular basis and treatment.黏多糖贮积症 III 型:分子基础与治疗。
Pediatr Endocrinol Diabetes Metab. 2021;27(3):201-208. doi: 10.5114/pedm.2021.109270.
7
An Engineered Mutant Zebrafish Recapitulates Molecular and Behavioural Pathobiology of Sanfilippo Syndrome A/MPS IIIA.工程化突变斑马鱼重现了黏多糖贮积症 IIIA 型(Sanfilippo 综合征 A/MPS IIIA)的分子和行为病理生物学特征。
Int J Mol Sci. 2021 May 31;22(11):5948. doi: 10.3390/ijms22115948.
8
Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α--Acetylglucosamine-6-Sulfatase in Neonatal Mice.用重组人α-乙酰氨基葡萄糖-6-硫酸酯酶治疗新生期小鼠黏多糖贮积症 III 型。
Mol Pharm. 2021 Jan 4;18(1):214-227. doi: 10.1021/acs.molpharmaceut.0c00831. Epub 2020 Dec 15.
9
Novel therapies for mucopolysaccharidosis type III.用于 III 型黏多糖贮积症的新型疗法。
J Inherit Metab Dis. 2021 Jan;44(1):129-147. doi: 10.1002/jimd.12316. Epub 2020 Sep 28.
10
Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease.桑菲力波综合征的主要负担——神经退行性变和认知衰退的分子基础
J Clin Med. 2020 Jan 27;9(2):344. doi: 10.3390/jcm9020344.